Anavex Life Sciences Corp (AVXL)

[falconer66a]

Neonatal Administration for Rett Syndrome Will Be Successful

And who knows, maybe if taken early enough it will allow for normal speech development.

In the treatment of Rett syndrome with blarcamesine, this is very important.

Of course, whatever symptomatic suppression blarcamesine will bring to older girls suffering from Rett syndrome will be joyfully welcomed. For example, it was noted in the Australian videos that blarcamesine reduced the frequency or severity of seizures in the debilitated girls. That, alone, is a wonderful therapeutic success — worthy alone for the drug’s eventual approval in the US.

But the drug’s greatest therapeutic successes will be when it is administered before functional deformities get irretrievably locked or gown in. Rett syndrome can be diagnosed either at birth, or even prenatally, while the infant is still in utero. With such, blarcamesine can be administered at the earliest convenience, yielding the very best therapeutic outcomes. With blarcamesine, neonates (new borns) with Rett will fare far better, with results that endure.